Development of a cytomegalovirus vaccine: lessons from recent clinical trials (Q34451960)

2 August 2017

1 reference

title

Development of a cytomegalovirus vaccine: lessons from recent clinical trials (English)

1 reference

2 August 2017

0 references

0 references

1

Gonczol E

1 reference

2 August 2017

Plotkin S

2

1 reference

PubMed ID

11727514

2 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Biological Therapy

2 August 2017

1 reference

2 August 2017

1

1 reference

2 August 2017

401-412

1 reference

2 August 2017

3

1 reference

Vaccination against cytomegalovirus, the changeling demon

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Clinical Trials of Immunization with the Towne 125 Strain of Human Cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Cytomegalovirus vaccine virus (Towne strain) does not induce latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

The immunogenicity of human and murine cytomegaloviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Biological features of genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

DNA and RNA-based vaccines: principles, progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.401

21 January 2018

Identifiers

DOI

10.1517/14712598.1.3.401

1 reference

2 August 2017

1 reference

PubMed ID

11727514